As it shops for new deals, Akcea hires former GSK exec as COO

Natalie Grover

Reporter

In an unexpected twist in September, a trifecta of senior executives running Akcea — CEO Paula Soteropoulos, president Sarah Boyce and COO Jeffrey Goldberg — left the Boston drugmaker in one fell swoop.

The board of the Ionis majority-owned spinoff swooped in to place Damien McDevitt — the chief business officer of the California company — in the interim chief spot. He will now be joined by Alex Howarth who will take on the role of COO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

As it shops for new deals, Akcea hires former GSK exec as COO

Natalie Grover

Reporter

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

As it shops for new deals, Akcea hires for­mer GSK ex­ec as COO

Natalie Grover

Reporter

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Sen­a­tors want to know more on why No­vo is dis­con­tin­u­ing its in­sulin Lev­emir

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

As it shops for new deals, Akcea hires former GSK exec as COO

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal